e-Therapeutics plc Directorate Change (0166X)

TIDMETX

RNS Number : 0166X

e-Therapeutics plc

16 February 2017

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Directorate Change

Oxford, UK, 16 February 2017 - e-Therapeutics plc (AIM:ETX) announced today that Sean Nicolson, Executive Director & Company Secretary will be leaving in order to focus on other business commitments.

Iain Ross, Chairman said:

"Over the last year this business has gone through a period of transition culminating with the recent announcement of the appointment of Dr. Raymond Barlow as our new CEO. During this period Sean has made a significant contribution and will leave the Company on 28 February. I would like to thank him personally for his support and to wish him every success in the future."

-Ends-

Contacts:

 
 e-Therapeutics plc                              Tel: +44 (0) 1993 883 125 
  Iain Ross, Chairman                             www.etherapeutics.co.uk 
  Steve Medlicott, Finance Director 
 Numis Securities Limited                        Tel: +44 (0) 207 260 1000 
  Michael Meade / Freddie Barnfield (Corporate    www.numis.com 
  Finance) 
  James Black (Corporate Broking) 
 Instinctif Partners                             Tel: +44 (0) 207 457 2020 
  Melanie Toyne-Sewell / Alex Shaw                Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.

e-Therapeutics has a variety of preclinical stage assets, ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway inhibition; ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects.

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford, UK. For more information, visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABIGDDLSBBGRU

(END) Dow Jones Newswires

February 16, 2017 02:00 ET (07:00 GMT)

E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024